Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.

Next Previous
X
Search
Trial Profile

A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic Parkinson's Disease with motor fluctuations, treated with a stable dose of levodopa and who may be receiving concomitant treatment with stable doses of a dopamine agonist, an anticholinergic and/or amantadine.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Safinamide (Primary) ; Levodopa
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms SETTLE
  • Sponsors Merck Serono; Newron Pharmaceuticals

    • Most Recent Events

    • 09 Dec 2023 Results of post hoc analysis of SETTLE and XINDI trial assessing the effects of safinamide in chinese and non-chinese patients with parkinson's disease (440 non-Chinese and 109 Chinese patients in the SETTLE study, and 305 Chinese patients in the XINDI trial ) published in the Advances in Therapy.
    • 18 Sep 2022 Results of post hoc analysis evaluating the efficacy and safety outcomes of safinamide as a levodopa adjunct therapy, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
    • 30 Jul 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record (29 Mar 2012).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top